RE:RE:RE:RE:RE:ONCY to make an "Oral Presentation" on Bracelet-1 at ASCOShould read: : ....in advance of the addition of the PD-(L)1 immune checkpoint inhibitor (avelumab).
Both Roche and Pfizer/Merck KGaA should be very pleased with these results and I would expect them to make a move on ONCY very soon.